Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 13.45
OGXI's Cash to Debt is ranked higher than
68% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. OGXI: 13.45 )
OGXI' s 10-Year Cash to Debt Range
Min: 0.88   Max: No Debt
Current: 13.45

Equity to Asset 0.61
OGXI's Equity to Asset is ranked higher than
68% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OGXI: 0.61 )
OGXI' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.92
Current: 0.61

0.33
0.92
F-Score: 3
Z-Score: -2.98
M-Score: -4.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -108.67
OGXI's Operating margin (%) is ranked higher than
70% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. OGXI: -108.67 )
OGXI' s 10-Year Operating margin (%) Range
Min: -48696   Max: 9.64
Current: -108.67

-48696
9.64
Net-margin (%) -96.77
OGXI's Net-margin (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. OGXI: -96.77 )
OGXI' s 10-Year Net-margin (%) Range
Min: -46544   Max: 10.24
Current: -96.77

-46544
10.24
ROE (%) -78.94
OGXI's ROE (%) is ranked higher than
59% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. OGXI: -78.94 )
OGXI' s 10-Year ROE (%) Range
Min: -85.95   Max: 12.27
Current: -78.94

-85.95
12.27
ROA (%) -47.85
OGXI's ROA (%) is ranked higher than
62% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. OGXI: -47.85 )
OGXI' s 10-Year ROA (%) Range
Min: -74.08   Max: 7.33
Current: -47.85

-74.08
7.33
ROC (Joel Greenblatt) (%) -5959.95
OGXI's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. OGXI: -5959.95 )
OGXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18547.17   Max: 48.05
Current: -5959.95

-18547.17
48.05
Revenue Growth (3Y)(%) 38.90
OGXI's Revenue Growth (3Y)(%) is ranked higher than
94% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. OGXI: 38.90 )
OGXI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 628.7
Current: 38.9

0
628.7
EBITDA Growth (3Y)(%) -10.80
OGXI's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. OGXI: -10.80 )
OGXI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -74.3   Max: 104.5
Current: -10.8

-74.3
104.5
EPS Growth (3Y)(%) -1.30
OGXI's EPS Growth (3Y)(%) is ranked higher than
78% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. OGXI: -1.30 )
OGXI' s 10-Year EPS Growth (3Y)(%) Range
Min: -74.7   Max: 96.2
Current: -1.3

-74.7
96.2
» OGXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

OGXI Guru Trades in Q1 2014

Jim Simons 89,522 sh (+5.57%)
» More
Q2 2014

OGXI Guru Trades in Q2 2014

Jean-Marie Eveillard 574,712 sh (New)
George Soros 30,800 sh (New)
Jim Simons 279,922 sh (+212.69%)
» More
Q3 2014

OGXI Guru Trades in Q3 2014

George Soros Sold Out
Jean-Marie Eveillard 515,512 sh (-10.30%)
Jim Simons 236,415 sh (-15.54%)
» More
Q4 2014

OGXI Guru Trades in Q4 2014

Jim Simons 385,483 sh (+63.05%)
Jean-Marie Eveillard 515,512 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with OGXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.50
OGXI's P/B is ranked higher than
95% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. OGXI: 1.50 )
OGXI' s 10-Year P/B Range
Min: 0.3   Max: 9
Current: 1.5

0.3
9
P/S 1.30
OGXI's P/S is ranked higher than
97% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. OGXI: 1.30 )
OGXI' s 10-Year P/S Range
Min: 0.59   Max: 47.95
Current: 1.3

0.59
47.95
EV-to-EBIT -0.09
OGXI's EV-to-EBIT is ranked higher than
76% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OGXI: -0.09 )
OGXI' s 10-Year EV-to-EBIT Range
Min: -340.1   Max: 15.6
Current: -0.09

-340.1
15.6
Current Ratio 2.51
OGXI's Current Ratio is ranked higher than
62% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. OGXI: 2.51 )
OGXI' s 10-Year Current Ratio Range
Min: 1.87   Max: 12.9
Current: 2.51

1.87
12.9
Quick Ratio 2.51
OGXI's Quick Ratio is ranked higher than
64% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. OGXI: 2.51 )
OGXI' s 10-Year Quick Ratio Range
Min: 1.87   Max: 12.9
Current: 2.51

1.87
12.9
Days Sales Outstanding 76.40
OGXI's Days Sales Outstanding is ranked higher than
79% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. OGXI: 76.40 )
OGXI' s 10-Year Days Sales Outstanding Range
Min: 8.27   Max: 312.07
Current: 76.4

8.27
312.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.00
OGXI's Price/Net Cash is ranked higher than
98% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. OGXI: 2.00 )
OGXI' s 10-Year Price/Net Cash Range
Min: 0.75   Max: 10.23
Current: 2

0.75
10.23
Price/Net Current Asset Value 1.70
OGXI's Price/Net Current Asset Value is ranked higher than
98% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. OGXI: 1.70 )
OGXI' s 10-Year Price/Net Current Asset Value Range
Min: 0.72   Max: 17.04
Current: 1.7

0.72
17.04
Price/Tangible Book 1.40
OGXI's Price/Tangible Book is ranked higher than
97% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. OGXI: 1.40 )
OGXI' s 10-Year Price/Tangible Book Range
Min: 0.47   Max: 30.82
Current: 1.4

0.47
30.82
Price/Median PS Value 0.20
OGXI's Price/Median PS Value is ranked higher than
99% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. OGXI: 0.20 )
OGXI' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 507.99
Current: 0.2

0.13
507.99
Earnings Yield (Greenblatt) -1126.50
OGXI's Earnings Yield (Greenblatt) is ranked lower than
74% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. OGXI: -1126.50 )
OGXI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1126.5   Max: 5864.5
Current: -1126.5

-1126.5
5864.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SP4A.Germany,
OncoGenex Pharmaceuticals Inc was incorporated in California in October 1991 and reorganized as a Delaware corporation in March 1995. The Company is a biopharmaceutical company. The Company is engaged in the development and commercialization of new therapies that address treatment resistance in cancer patients. The Company has developed a pipeline of late-stage product candidates that are designed to block the production of specific proteins that promote treatment resistance in cancer. The Company has three product candidates in pipeline including custirsen, apatorsen and OGX-225, each of which has a distinct mechanism of action and represents a opportunity for cancer drug development. Of the product candidates in pipeline, custirsen and apatorsen are clinical-stage assets being evaluated in two phase 3 studies and five phase 2 studies. The Company's product candidate's custirsen, apatorsen and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments. Custirsen is currently being evaluated in two phase 3 trials; one in patients with prostate cancer and one in patients with non-small cell lung cancer, or NSCLC. Custirsen is designed to inhibit the production of clusterin, a protein that promotes survival of cancer cells when overexpressed in a variety of tumors. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27, or Hsp27, a cell-survival protein expressed in many types of cancers including bladder, non-small cell lung, pancreatic, prostate and breast cancers. OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that affect the growth of cancer cells when overexpressed. The Company faces competition from pharmaceutical, biopharmaceutical and biotechnology companies that are researching and marketing products designed to address cancer indications. The Company owns trademarks registered in the United States, namely word marks ONCOGENEX, ORCA, Spruce, and Rainier, and design marks ORCA, Cedar, Pacific, Borealis-1, Borealis-2, and the helical totem element that accompanies the clinical trial trademarked identifiers. The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country.
» More Articles for OGXI

Headlines

Articles On GuruFocus.com
George Soros Had A Mixed Day On The Market Oct 30 2014 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 1 Jan 06 2011 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Dec 03 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 17 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 02 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 05 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q/A) May 10 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) May 06 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Nov 05 2009 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Apr 27 2015
OncoGenex Regains Rights to Custirsen from Teva Apr 27 2015
6:32 am OncoGenex executed a termination agreement with Teva Pharmaceuticals (Apr 27 2015
OncoGenex Regains Rights to Custirsen from Teva Apr 27 2015
OncoGenex Regains Rights to Custirsen from Teva Apr 27 2015
OncoGenex Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference Apr 09 2015
OncoGenex Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference Apr 09 2015
OncoGenex Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference Apr 09 2015
ONCOGENEX PHARMACEUTICALS, INC. Financials Apr 07 2015
OncoGenex Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Mar 26 2015
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 Mar 26 2015
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 26 2015
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 Mar 26 2015
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 Mar 26 2015
Q4 2014 OncoGenex Pharmaceuticals Inc Earnings Release - After Market Close Mar 26 2015
OncoGenex to Report Financial Results for Fourth Quarter and Year End 2014 on March 26, 2015 Mar 23 2015
OncoGenex to Report Financial Results for Fourth Quarter and Year End 2014 on March 26, 2015 Mar 23 2015
OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce™ Clinical Trial... Feb 24 2015
OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce™ Clinical Trial... Feb 24 2015
OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce™ Clinical Trial... Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK